Safety issues with drug therapies for autism spectrum disorders

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 10, 2005, Pages 32-37

  McCracken, James T ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CENTRAL STIMULANT AGENT; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; CLOZAPINE; ESCITALOPRAM; FLUOXETINE; GLUCOSE; GUANFACINE; HERBACEOUS AGENT; METHYLPHENIDATE; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRIACYLGLYCEROL; VITAMIN; ZIPRASIDONE;

AGITATION; ANOREXIA; ANXIETY; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; CARDIOTOXICITY; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIABETES MELLITUS; DROWSINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOMANIA; HYPOTENSION; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LIVER TOXICITY; MANIA; MENTAL INSTABILITY; NAUSEA AND VOMITING; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; REVIEW; SEDATION; SLEEP DISORDER; TIC; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; DRUG MONITORING; DRUG THERAPY; HUMANS; LONG-TERM CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 31144434282     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Langworthy-Lam KS, Aman G, Van Bourgondien ME. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the autism society of North Carolina. J Child Adolesc Psychopharmacol 2002;12:311-321
2. Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord 2003;33:527-534
3. Martin A, Scahill L, Klin A, et al. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 1999;38:923-931
4. Aman MG, Arnold LE, McDougle CJ, et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. In press
5. King BH. Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders. J Autism Dev Disord 2000;33:527-534
6. Fatemi SH, Realmuto GM, Khan L, et al. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998;28:303-307
7. Cook EH Jr, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992;31:739-745
8. Brodkin ES, McDougle CJ, Naylor ST, et al. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol 1997;7:109-121
9. Posey DJ, Guenin KD, Kohn AE, et al. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 2001;11:267-277
10. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000;30:245-255
11. Research Units on Pediatric Pharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62:1266-1274
12. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004;113:762-769
13. Biederman J, Faraone S, Monuteaux MC, et al. Growth deficits and attention-deficit/hyperactivity disorder revisited: impact of gender, development, and treatment. Pediatrics 2003;111(5, pt 1):1010-1016
14. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:e634-e641
15. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321
16. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005;162:1361-1369
17. Martin A, Scahill L, Anderson GM, et al. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 2004;161:1125-1127
18. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
19. Aman M, Cronin P, Hollway J, et al. 18-Month follow-up of participants in the RUPP autism risperidone study. Presented at the 51st Annual Meeting of the American Society of Child and Adolescent Psychiatry; October 19-24, 2004; Washington, DC. Abstract 53C
20. Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159:1337-1346
21. Findling RL, Aman MG, Eerdekens M, et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 2004;161:677-684
22. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601
23. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158:1067-1074
24. Scahill L, Tierney M, Rodowski J, et al. Guanfacine in the treatment of hyperactivity in pervasive developmental disorders. Presented at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 19-24,2004; Washington, DC. Abstract 48E
25. Paxil [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2005
26. Prozac [prescribing information]. Indianapolis, Ind: Eli Lilly and Company; 2005
27. Celexa [prescribing information]. St. Louis, Mo: Forest Pharmaceuticals, Inc; 2005
28. Lexapro [prescribing information]. St. Louis, Mo: Forest Pharmaceuticals, Inc; 2005
29. Zoloft [prescribing information]. New York, NY: Pfizer Inc; 2005
30. 19F Magnetic Resonance Spectroscopy. Am J Psychiatry 1998;155:380-384
31. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004 (suppl 7);65:1-18